Amivantamab vs Alternative Therapies in Patients with EGFR Exon 20–Mutated NSCLC

home / between-the-lines / amivantamab-vs-alternative-therapies-in-patients-with-egfr-exon-20-mutated-nsclc

Joshua K. Sabari, MD, and Helena A. Yu, MD, discuss the evolving treatment landscape in non–small cell lung cancer for patients with EGFR exon 20 insertion mutations and results from a real-world study that may impact the field.